{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:14:27Z","timestamp":1781223267695,"version":"3.54.1"},"reference-count":56,"publisher":"American Association for the Advancement of Science (AAAS)","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":31,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011057","name":"National Center for Genetic Engineering and Biotechnology","doi-asserted-by":"publisher","award":["P-2051635"],"award-info":[{"award-number":["P-2051635"]}],"id":[{"id":"10.13039\/501100011057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["csbj.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comput Struct Biotechnol J"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.csbj.2022.02.001","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T02:46:34Z","timestamp":1643942794000},"page":"882-890","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Identification of novel SARS-CoV-2 RNA dependent RNA polymerase (RdRp) inhibitors: From\n                    <i>in silico<\/i>\n                    screening to experimentally validated inhibitory activity"],"prefix":"10.34133","volume":"20","author":[{"given":"Tanaporn","family":"Uengwetwanit","sequence":"first","affiliation":[{"name":"National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency, Pathum Thani 12120, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nopporn","family":"Chutiwitoonchai","sequence":"additional","affiliation":[{"name":"National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency, Pathum Thani 12120, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanin","family":"Wichapong","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 6200 MD Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitsara","family":"Karoonuthaisiri","sequence":"additional","affiliation":[{"name":"National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency, Pathum Thani 12120, Thailand"},{"name":"Institute for Global Food Security, Queen's University, Belfast, Biological Sciences Building, 19 Chlorine Gardens, Belfast BT9 5DL, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108891"},{"key":"e_1_3_5_3_2","article-title":"Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence","author":"Puranik A.","year":"2021","unstructured":"Puranik A., Lenehan P.J., Silvert E., Niesen M.J.M., Corchado-Garcia J., O\u2019Horo J.C. et al: Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv 2021; .","journal-title":"medRxiv"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-00396-2"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06540-11"},{"key":"e_1_3_5_6_2","first-page":"732","article-title":"From SARS, MERS to COVID-19: A journey to understand bat coronaviruses","volume":"205","author":"Shi Z.","year":"2021","unstructured":"Shi Z.: From SARS, MERS to COVID-19: A journey to understand bat coronaviruses. Bull Acad Natl Med 2021; 205: 732.","journal-title":"Bull Acad Natl Med"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101830"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-012-1404-x"},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fgene.2017.00125","article-title":"Origin and Evolution of RNA-Dependent RNA Polymerase","volume":"8","author":"de Farias S.T.","year":"2017","unstructured":"de Farias S.T., dos Santos Junior A.P., R\u00eago T.G. and Jos\u00e9 M.V.: Origin and Evolution of RNA-Dependent RNA Polymerase. Front Genet 2017; 8: 125.","journal-title":"Front Genet"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2368-8"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"e4166","DOI":"10.1093\/cid\/ciaa1041","article-title":"Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care","volume":"73","author":"Olender S.A.","year":"2021","unstructured":"Olender S.A., Perez K.K., Go A.S., Balani B., Price-Haywood E.G., Shah N.S. et al: Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care. Clin Infect Dis 2021; 73: e4166.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106272"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13060963"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116846"},{"key":"e_1_3_5_16_2","doi-asserted-by":"crossref","DOI":"10.4103\/ija.IJA_149_21","article-title":"Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study","volume":"65","author":"Mahajan L.","year":"2021","unstructured":"Mahajan L., Singh A.P. and Gifty : Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study. Indian J Anaesthesia 2021; 65.","journal-title":"Indian J Anaesthesia"},{"key":"e_1_3_5_17_2","first-page":"3784","article-title":"Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience. Journal of","volume":"10","author":"Russo A.","year":"2021","unstructured":"Russo A., Binetti E., Borrazzo C., Cacciola E.G., Battistini L., Ceccarelli G. et al: Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience. Journal of. Clinical Medicine 2021; 10: 3784.","journal-title":"Clinical Medicine"},{"key":"e_1_3_5_18_2","article-title":"Why remdesivir failed: preclinical assumptions overestimate the clinical efficacy of remdesivir for COVID-19 and ebola","volume":"65","author":"Yan V.C.","year":"2021","unstructured":"Yan V.C. and Muller F.L.: Why remdesivir failed: preclinical assumptions overestimate the clinical efficacy of remdesivir for COVID-19 and ebola. Antimicrob Agents Chemother 2021; 65.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","article-title":"Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial","volume":"22","author":"Ader F.","year":"2021","unstructured":"Ader F., Bouscambert-Duchamp M., Hites M., Peiffer-Smadja N., Poissy J., Belhadi D. et al: Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis 2021; 22: 209.","journal-title":"Lancet Infect Dis"},{"key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1208\/s12248-020-00459-8","article-title":"Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit","volume":"22","author":"Sun D.","year":"2020","unstructured":"Sun D.: Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit. Aaps j 2020; 22: 77.","journal-title":"Aaps j"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109450"},{"key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000518440","article-title":"Remdesivir: A closer look at its effect in COVID-19 pandemic","volume":"106","author":"Taha H.R.","year":"2021","unstructured":"Taha H.R., Keewan N., Slati F. and Al-Sawalha N.A.: Remdesivir: A closer look at its effect in COVID-19 pandemic. Pharmacology 2021; 106: 462.","journal-title":"Pharmacology"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-10-421"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-5-113"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts091"},{"key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2105-4-29","article-title":"MatGAT: An application that generates similarity\/identity matrices using protein or DNA sequences","volume":"4","author":"Campanella J.J.","year":"2003","unstructured":"Campanella J.J., Bitincka L. and Smalley J.: MatGAT: An application that generates similarity\/identity matrices using protein or DNA sequences. BMC Bioinf 2003; 4: 29.","journal-title":"BMC Bioinf"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.0c00675"},{"key":"e_1_3_5_28_2","article-title":"Open Babel: An open chemical toolbox","volume":"3","author":"O\u2019Boyle N.M.","year":"2011","unstructured":"O\u2019Boyle N.M., Banck M., James C.A., Morley C., Vandermeersch T. and Hutchison G.R.: Open Babel: An open chemical toolbox. J Cheminf 2011; 3.","journal-title":"J Cheminf"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1560"},{"key":"e_1_3_5_30_2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/prot.10465","article-title":"Improved protein-ligand docking using GOLD","volume":"52","author":"Verdonk M.L.","year":"2003","unstructured":"Verdonk M.L., Cole J.C., Hartshorn M.J., Murray C.W. and Taylor R.D.: Improved protein-ligand docking using GOLD. Proteins 2003; 52: 609.","journal-title":"Proteins"},{"key":"e_1_3_5_31_2","unstructured":"Dassault Systemes BIOVIA BIOVIA Discovery Studio Visualizer v.4.0. 2021 San Diego: Dassault Systemes 2021. Available from: https:\/\/discover.3ds.com\/discovery-studio-visualizer-download"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2021.01.026"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01952"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2020.09.006"},{"key":"e_1_3_5_35_2","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1099\/vir.0.000184","article-title":"Genetic manipulation of porcine epidemic diarrhoea virus recovered from a full-length infectious cDNA clone","volume":"96","author":"Jengarn J.","year":"2015","unstructured":"Jengarn J., Wongthida P., Wanasen N., Frantz P.N., Wanitchang A. and Jongkaewwattana A.: Genetic manipulation of porcine epidemic diarrhoea virus recovered from a full-length infectious cDNA clone. J Gen Virol 2015; 96: 2206.","journal-title":"J Gen Virol"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0282-0"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10280-3"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2016.09.001"},{"key":"e_1_3_5_39_2","article-title":"Surveillance of bat coronaviruses in Kenya identifies relatives of human coronaviruses NL63 and 229E and their recombination history","volume":"91","author":"Tao Y.","year":"2017","unstructured":"Tao Y., Shi M., Chommanard C., Queen K., Zhang J., Markotter W. et al: Surveillance of bat coronaviruses in Kenya identifies relatives of human coronaviruses NL63 and 229E and their recombination history. J Virol 2017; 91.","journal-title":"J Virol"},{"key":"e_1_3_5_40_2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/B978-0-12-809633-8.21501-X","article-title":"Human coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae)","author":"Liu D.X.","year":"2021","unstructured":"Liu D.X., Liang J.Q. and Fung T.S.: Human coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae). Encyclop Virol 2021; : 428.","journal-title":"Encyclop Virol"},{"key":"e_1_3_5_41_2","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91662-w","article-title":"Concurrent mutations in RNA-dependent RNA polymerase and spike protein emerged as the epidemiologically most successful SARS-CoV-2 variant","volume":"11","author":"Ilmj\u00e4rv S.","year":"2021","unstructured":"Ilmj\u00e4rv S., Abdul F., Acosta-Guti\u00e9rrez S., Estarellas C., Galdadas I., Casimir M. et al: Concurrent mutations in RNA-dependent RNA polymerase and spike protein emerged as the epidemiologically most successful SARS-CoV-2 variant. Sci Rep 2021; 11.","journal-title":"Sci Rep"},{"key":"e_1_3_5_42_2","doi-asserted-by":"crossref","first-page":"e9587","DOI":"10.7717\/peerj.9587","article-title":"RdRp mutations are associated with SARS-CoV-2 genome evolution","volume":"8","author":"Eskier D.","year":"2020","unstructured":"Eskier D., Karak\u00fclah G., Suner A. and Oktay Y.: RdRp mutations are associated with SARS-CoV-2 genome evolution. PeerJ 2020; 8: e9587.","journal-title":"PeerJ"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.0c00501"},{"key":"e_1_3_5_44_2","unstructured":"World Health Organization. Tracking SARS-CoV-2 variants. 2021 [cited 2021 November 26]; Available from: https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/."},{"key":"e_1_3_5_45_2","unstructured":"World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. 2021 [cited 2021 26 November]; Available from: https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern."},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2004.11.007"},{"key":"e_1_3_5_47_2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nrd.2018.197","article-title":"Re-assessing the rule of 5, two decades on","volume":"17","author":"Mullard A.","year":"2018","unstructured":"Mullard A.: Re-assessing the rule of 5, two decades on. Nat Rev Drug Discov 2018; 17: 777.","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_3_5_48_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198045","article-title":"Porcine epidemic diarrhea virus (PEDV): An update on etiology, transmission, pathogenesis, and prevention and control","volume":"286","author":"Jung K.","year":"2020","unstructured":"Jung K., Saif L.J. and Wang Q.: Porcine epidemic diarrhea virus (PEDV): An update on etiology, transmission, pathogenesis, and prevention and control. Virus Res 2020; 286: 198045.","journal-title":"Virus Res"},{"key":"e_1_3_5_49_2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan T.P.","year":"2017","unstructured":"Sheahan T.P., Sims A.C., Graham R.L., Menachery V.D., Gralinski L.E., Case J.B. et al: Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9.","journal-title":"Sci Transl Med"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.11.043"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104541"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-021-00362-2"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212134"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2021.06.005"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1039\/D0RA04743K"},{"key":"e_1_3_5_56_2","article-title":"Comprehensive Summary Supporting Clinical Investigation of GS-441524 for Covid-19 Treatment","author":"Yan V.","year":"2020","unstructured":"Yan V. and Florian M.: Comprehensive Summary Supporting Clinical Investigation of GS-441524 for Covid-19 Treatment. OSF Preprints. 2020; .","journal-title":"OSF Preprints."},{"key":"e_1_3_5_57_2","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(21)00216-0","article-title":"Estimating clinical SARS-CoV-2 infectiousness in Vero E6 and primary airway epithelial cells","volume":"2","author":"Essaidi-Laziosi M.","year":"2021","unstructured":"Essaidi-Laziosi M., Javier Perez Rodriguez F., Hulo N., Jacquerioz F., Kaiser L. and Eckerle I.: Estimating clinical SARS-CoV-2 infectiousness in Vero E6 and primary airway epithelial cells. Lancet Microbe 2021; 2.","journal-title":"Lancet Microbe"}],"container-title":["Computational and Structural Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037022000381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037022000381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1016\/j.csbj.2022.02.001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T12:58:10Z","timestamp":1779022690000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1016\/j.csbj.2022.02.001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":56,"alternative-id":["10.1016\/j.csbj.2022.02.001"],"URL":"https:\/\/doi.org\/10.1016\/j.csbj.2022.02.001","relation":{},"ISSN":["2001-0370"],"issn-type":[{"value":"2001-0370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of novel SARS-CoV-2 RNA dependent RNA polymerase (RdRp) inhibitors: From in silico screening to experimentally validated inhibitory activity","name":"articletitle","label":"Article Title"},{"value":"Computational and Structural Biotechnology Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.csbj.2022.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.","name":"copyright","label":"Copyright"}]}}